Table 3.
CIN Incidence and Clinical Outcomes According to NT‐proBNP Quartiles
| Outcomes | NT‐proBNP Quartiles | P Value | |||
|---|---|---|---|---|---|
| Q1 (n=562) (<65 pg/mL) | Q2 (n=562) (65 to 247.5 pg/mL) | Q3 (n=562) (247.5 to 976 pg/mL) | Q4 (n=562) (≥976 pg/mL) | ||
| CIN | |||||
| Scr increase ≥0.5 mg/dL or ≥25%, n (%) | 40 (7.1) | 41 (7.3) | 45 (8.0) | 74 (13.2) | <0.001 |
| Scr increase ≥0.5 mg/dL, n (%) | 3 (0.5) | 7 (1.2) | 7 (1.2) | 33 (5.9) | <0.001 |
| Scr increase ≥0.3 mg/dL, n (%) | 9 (1.6) | 18 (3.2) | 22 (3.9) | 57 (10.3) | <0.001 |
| Scr increase ≥0.3 mg/dL or ≥50%, n (%) | 9 (1.6) | 18 (3.2) | 22 (3.9) | 57 (10.3) | <0.001 |
| Death, n (%) | 1 (0.2) | 0 (0.0) | 1 (0.2) | 10 (1.8) | <0.001 |
| Require RRT, n (%) | 0 (0.0) | 2 (0.4) | 1 (0.2) | 7 (1.2) | 0.023 |
CIN indicates contrast‐induced nephropathy; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; RRT, renal replacement therapy; Scr, serum creatinine.